openPR Logo
Press release

How the Cure for Herpes Became Mired in Controversy. The latest chapter in the battle between Big Pharma and Synergy Pharmaceuticals

How the Cure for Herpes Became Mired in Controversy. The latest

Over several decades, the Food and Drug Administration (FDA) has gone to great lengths to maintain its longstanding relationship with major pharmaceutical companies, namely by approving numerous medications. (Many of those approvals, for prescription medicines like Isotretinoin, Pemoline, and Propoxyphene, were eventually recalled after causing patient deaths or irreversible damage.) And this dynamic hasn’t been limited to medical treatments. Despite extensive research that shows sugar is the leading cause of heart disease and diabetes, the FDA has gone so far as to endorse it, fearing the ramifications that a warning label could have on agriculture producers and the greater food production industry. Given these historical patterns, it comes as no surprise that the FDA is opposed to natural medicine, especially when alternative treatments threaten to cut into pharmaceutical companies’ market share.

Synergy Pharmaceuticals is one such company currently facing pushback from the FDA. Its name is a bit confusing considering that its catalog features only natural vitamins. Even more confusing is that two companies are sharing the name. The New York-based Synergy Pharmaceuticals went bust in 2016, while Synergy Pharmaceuticals Australia stayed in business. Yet the Australian company has still been linked to controversy and supply concerns from its onset.

In November 2020, Synergy Pharmaceuticals Australia did shut down temporarily after facing COVID-19-related supply chain issues. Thankfully, after a change of ownership in May 2021, the company resumed operations.

However, it’s Synergy’s most high-profile product that has generated controversy, not its most recent business troubles. The company bills itself as the producer of the world’s first cure for the herpes simplex virus. This claim has, unsurprisingly, attracted an incredible amount of critique and cynicism. But the degree to which the naysayers, the pharmaceutical industry, and conventional medicine practitioners have scrutinized Synergy’s treatment is nearly insurmountable. In any other scenario, one would consider such a development a monumental leap forward in herpes sufferers’ fight against the virus. Instead, Synergy Pharmaceuticals has found itself in the center of a vicious battle, spearheaded by proponents of conventional medicine.

Their pushback is in opposition to the treatment’s proven success. In reviewing online feedback and forum discussions to date, there’s a contingent of patients who have clearly been cured and who can vouch for the treatment’s ability to eradicate the virus. Still, there are just as many who refute the treatment’s effectiveness. Those in the latter camp are mostly individuals who haven’t used the treatment but feel strongly that natural medicine is incapable of curing any virus. In the views of those who are opposed, they would only trust their local doctor or a more conventional medical institution to validate a cure. Their resistance is naïve, as more than 40% of pharmaceutical drugs are derived from plants. For example, penicillin was created from Penicillium chrysogenum, a species of fungus that is essentially mold. Morphine is crafted from #opium# poppies, aspirin from willow bark, and so on. Natural and conventional medicines have far more in common than many people realize, including those waging the battle against Synergy Pharmaceuticals.

To investigate, we compared the effectiveness of Synergy’s treatment to that of Acyclovir, the most commonly used suppressant medication for herpes patients. The most startling difference between the two treatments was that Acyclovir had to be used every day to suppress herpes outbreaks or cold sores. The medication didn’t provide a long-term solution unless it was administered regularly, and even then, it had only a modest rate of actually stopping outbreaks from occurring. By comparison, Synergy’s product reduced herpes outbreaks and cold sores permanently. In one independent study, those who’d suffered frequent outbreaks on a monthly or bimonthly basis went on to have no further outbreaks or just one or two outbreaks per year. These results were measured post-treatment once the person had completed a six-month clinical trial. These findings suggest that the treatment’s benefit remained intact for patients after the protocol was finished.

Furthermore, one only needs to assess the long list of Acyclovir side effects to determine whether it’s worth the financial outlay and health implications. Given that Synergy’s natural product has the potential for only a handful of mild side effects and costs far less, explaining the difference between the two products is like comparing apples to oranges.

From an external perspective, however, Synergy has clearly been unable to capitalize on its product’s ability to cure people of herpes due to what can only be described as poor marketing. This is understandable when taking into account that advertising via mainstream media or in medical centers is only permitted for drugs approved by the FDA. This amounts to a considerable shame, preventing people who are genuinely seeking help from accessing the product, due only to marketing limitations and the conventional medicine monopoly. To remedy this, Synergy conducted trials, and Yale students also carried out an independent study, all designed to determine if Synergy’s product does what it claims to do. The results from both avenues of research supported the effectiveness of the product, showing that it achieved the unimaginable in clearing infected patients of the herpes simplex virus. The percentage rate certainly works in Synergy’s favor, with an estimated 70% of trial subjects cured of herpes, but even having just 30% of participants cured would have been miraculous – it’s something that has never been accomplished by any means, let alone a pharmaceutical-based medication.

A groundbreaking innovation like Synergy’s product, one that eases the suffering of herpes simplex virus patients, should be embraced, not shunned or chastised. And undoubtedly, Synergy has traveled down a rocky road in navigating the response to its discovery. But there is some hope that this product will become increasingly mainstream in the coming years. It may take some expansion into the European market, as well as greater investment. Both aspects could bring Synergy’s vision to fruition, while also quieting some of the controversy and reducing the stigma associated with herpes.

Company Name: Synergy Pharmaceuticals
Contact Person: Marcus Torres (Media and Public Relations Manager)
Email: Media@synergy-pharmaceuticals.com
Phone: 03 8692 0025
Address: Collins Square Tower Five, 727 Collins Street, Melbourne, Victoria, 3008
Country: Australia
Website: www.synergy-pharmaceuticals.com

Though, to date, the ultimate takeaway is that changing the status quo – especially when it comes to shifting the way the medical community views natural medicine – is no easy task.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release How the Cure for Herpes Became Mired in Controversy. The latest chapter in the battle between Big Pharma and Synergy Pharmaceuticals here

News-ID: 2437558 • Views:

More Releases from Synergy Pharmaceuticals, Inc.

Synergy Pharmaceuticals Sues Rival Ironwood Pharmaceuticals in Drug Patent Case
NEW YORK - Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq:IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. The lawsuit alleges that after European Patent 1,379,224 was granted to Synergy but

More Releases for Synergy’s

Botanical Extracts Market Competitive Insights, Production and Demand 2021 to 20 …
Global Botanical Extracts Market – Growth, Trends, And Forecast (2021 – 2025) The report presents an in-depth assessment of the Global Botanical Extracts Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Global Botanical Extracts investments from 2021 till 2025. Click the link to get a Sample Copy
Global Constipation Market Report: 2016 Edition – New Report by Koncept Analyt …
The report, “Global Constipation Market” analyzes the currently prevailing condition of the market along with its future scope of development. Constipation is a common medical condition common among elderly and women, and is interpreted differently by patients and physicians. Constipation can be chronic, sometimes severe, and has a significant, even deliberating effect on the quality of life of a patient. Various treatment options are available for the treatment of constipation and
LaGuardia Plaza Hotel Joins NYC Carbon Challenge in Fight Against Climate Change
LaGuardia Plaza Hotel (LPH), the premier independent hotel located in the New York City (NYC) borough of Queens, announced participation in the NYC Carbon Challenge for Hotels, a partnership between the City and private and institutional sector leaders who have committed to reduce greenhouse gas emissions from their buildings by 30 percent or more in ten years. The program’s expansion to hotels is a key initiative in Mayor Bill de
Boston Fashion Night Gives the Retail Industry a Fresh New Look in One Night
Boston Fashion Night Boston Fashion Night Gives the Retail Industry a Fresh New Look in One Night! (BOSTON, MA) – For the first time ever, The SYNERGY Events is melding shopping, music, food, art, and fashion for the cosmopolitan people of Boston. Boston Fashion Night, an effort to stimulate the retail economy and promote Boston as an emerging fashion capital, will debut on Newbury Street on April 30th, 2011. This unconventional shopping
Synergy Restaurant Consultants: Synergy Restaurant Consultants Enables Magical E …
Synergy Restaurant Consultants Enables Magical Elves to Create “United Plates of America” for NBC. Many look to create the best new restaurant. However, in an innovative new TV series, the search is now on for the new culinary star to create those restaurants. Synergy Restaurant Consultants enabled Magical Elves, the producers of the Emmy Award Winning “Top Chef” to successfully pitch the next great restaurant competition show to NBC. The
Local Healthcare Services Company Expands With Grant
Through assistance from the Entech Innovation Center, a non-for-profit organization that assists local emerging businesses, Synergy Healthcare Resources LLC has obtained a grant for up to $100,000 in commercialized assistance. The Terre Haute Innovation Alliance and its partners: Indiana State University (ISU), Rose-Hulman Institute of Technology (RHIT), the Terra Haute Economic Development Corporation, and the City of Terre Haute, offered this grant, October 26, 2009. Synergy’s new presence in